Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2006;113:2301-2312
Published online before print May 8, 2006, doi: 10.1161/CIRCULATIONAHA.105.605121
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
113/19/2301    most recent
CIRCULATIONAHA.105.605121v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Heller, E. A.
Right arrow Articles by Gerszten, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heller, E. A.
Right arrow Articles by Gerszten, R. E.
Related Collections
Right arrow Animal models of human disease
Right arrow Genetically altered mice
Right arrow Growth factors/cytokines
Right arrow Mechanism of atherosclerosis/growth factors

(Circulation. 2006;113:2301-2312.)
© 2006 American Heart Association, Inc.


Molecular Cardiology

Chemokine CXCL10 Promotes Atherogenesis by Modulating the Local Balance of Effector and Regulatory T Cells

Eric A. Heller, MD; Emerson Liu, MD; Andrew M. Tager, MD; Qian Yuan, MD; Alexander Y. Lin, MD; Neil Ahluwalia, BS; Krister Jones, BA; Stephanie L. Koehn, BS; Vincent M. Lok, BA; Elena Aikawa, MD, PhD; Kathryn J. Moore, PhD; Andrew D. Luster, MD, PhD; Robert E. Gerszten, MD

From the Center for Immunology and Inflammatory Diseases (E.A.H., E.L., A.M.T., Q.Y., A.Y.L., N.A., K.J., A.D.L., R.E.G.), Cardiovascular Research Center (E.A.H., E.L., A.Y.L., N.A., R.E.G.), and Center for Molecular Imaging Research (V.M.L., E.A.), Massachusetts General Hospital, Charlestown, Mass, and Harvard Medical School, Boston, Mass; and Lipid Metabolism Unit & Endocrine Division (S.L.K., K.J.M.), Massachusetts General Hospital, Boston, Mass, and Harvard Medical School, Boston, Mass.

Correspondence to Robert E. Gerszten, MD, Cardiology Division and Center for Immunology & Inflammatory Diseases, Massachusetts General Hospital East-8307, 149 13th St, Charlestown, MA 02129. E-mail rgerszten{at}partners.org

Received December 9, 2005; revision received March 6, 2006; accepted March 9, 2006.

Background— Studies to define the overall contribution of lymphocytes to lesion formation in atherosclerosis-susceptible mice have demonstrated relatively subtle effects; the use of lymphocyte-deficient mice, however, compromises both the effector and regulatory arms of the immune system. Here, we tested the hypothesis that deletion of CXCL10 (IP-10), a chemokine specific for effector T cells that has been localized within atherosclerotic lesions, would significantly inhibit atherogenesis.

Methods and Results— Compound deficient Apoe–/–/Cxcl10–/– mice fed a Western-style diet for either 6 or 12 weeks demonstrated significant reductions in atherogenesis as compared with Apoe–/– controls, as assessed by both aortic en face and cross-sectional analyses. Immunohistochemical studies revealed a decrease in the accumulation of CD4+ T cells, whereas quantitative polymerase chain reaction analysis of lesion-rich aortic arches demonstrated a marked reduction in mRNA for CXCR3, the CXCL10 chemokine receptor. Although overall T-cell accumulation was diminished significantly, we found evidence to suggest that regulatory T-cell (Treg) numbers and activity were enhanced, as assessed by increased message for the Treg-specific marker Foxp3, as well as increases in immunostaining for the Treg-associated cytokines interleukin-10 and transforming growth factor-ß1. We also documented naturally occurring Treg cells in human atherosclerotic lesions.

Conclusions— We provide novel evidence for a functional role for the effector T-cell chemoattractant CXCL10 in atherosclerotic lesion formation by modulating the local balance of the effector and regulatory arms of the immune system.


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
J. Immunol.Home page
G. T. Schnickel, S. Bastani, G. R. Hsieh, A. Shefizadeh, R. Bhatia, M. C. Fishbein, J. Belperio, and A. Ardehali
Combined CXCR3/CCR5 Blockade Attenuates Acute and Chronic Rejection
J. Immunol., April 1, 2008; 180(7): 4714 - 4721.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Fougerat, S. Gayral, P. Gourdy, A. Schambourg, T. Ruckle, M. K. Schwarz, C. Rommel, E. Hirsch, J.-F. Arnal, J.-P. Salles, et al.
Genetic and Pharmacological Targeting of Phosphoinositide 3-Kinase-{gamma} Reduces Atherosclerosis and Favors Plaque Stability by Modulating Inflammatory Processes
Circulation, March 11, 2008; 117(10): 1310 - 1317.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Deola, M. C. Panelli, D. Maric, S. Selleri, N. I. Dmitrieva, C. Y. Voss, H. Klein, D. Stroncek, E. Wang, and F. M. Marincola
Helper B Cells Promote Cytotoxic T Cell Survival and Proliferation Independently of Antigen Presentation through CD27/CD70 Interactions
J. Immunol., February 1, 2008; 180(3): 1362 - 1372.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
E. J.A. van Wanrooij, S. C.A. de Jager, T. van Es, P. de Vos, H. L. Birch, D. A. Owen, R. J. Watson, E. A.L. Biessen, G. A. Chapman, T. J.C. van Berkel, et al.
CXCR3 Antagonist NBI-74330 Attenuates Atherosclerotic Plaque Formation in LDL Receptor-Deficient Mice
Arterioscler. Thromb. Vasc. Biol., February 1, 2008; 28(2): 251 - 257.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
D. Walcher, K. Hess, P. Heinz, K. Petscher, D. Vasic, U. Kintscher, M. Clemenz, M. Hartge, K. Raps, V. Hombach, et al.
Telmisartan Inhibits CD4-Positive Lymphocyte Migration Independent of the Angiotensin Type 1 Receptor via Peroxisome Proliferator-Activated Receptor-{gamma}
Hypertension, February 1, 2008; 51(2): 259 - 266.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Kwun, H. Hu, E. Schadde, D. Roenneburg, K. A. Sullivan, J. DeMartino, W. J. Burlingham, and S. J. Knechtle
Altered Distribution of H60 Minor H Antigen-Specific CD8 T Cells and Attenuated Chronic Vasculopathy in Minor Histocompatibility Antigen Mismatched Heart Transplantation in Cxcr3 / Mouse Recipients
J. Immunol., December 15, 2007; 179(12): 8016 - 8025.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Taleb, O. Herbin, H. Ait-Oufella, W. Verreth, P. Gourdy, V. Barateau, R. Merval, B. Esposito, K. Clement, P. Holvoet, et al.
Defective Leptin/Leptin Receptor Signaling Improves Regulatory T Cell Immune Response and Protects Mice From Atherosclerosis
Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2691 - 2698.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
I. Gotsman, R. Gupta, and A. H. Lichtman
The Influence of the Regulatory T Lymphocytes on Atherosclerosis
Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2493 - 2495.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
E. Galkina and K. Ley
Vascular Adhesion Molecules in Atherosclerosis
Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2292 - 2301.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A.O. Kraaijeveld, S.C.A. de Jager, W.J. de Jager, B.J. Prakken, S.R. McColl, I. Haspels, H. Putter, T.J.C. van Berkel, L. Nagelkerken, J.W. Jukema, et al.
CC Chemokine Ligand-5 (CCL5/RANTES) and CC Chemokine Ligand-18 (CCL18/PARC) Are Specific Markers of Refractory Unstable Angina Pectoris and Are Transiently Raised During Severe Ischemic Symptoms
Circulation, October 23, 2007; 116(17): 1931 - 1941.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. Aukrust, A. Yndestad, W. J. Sandberg, L. Gullestad, and J. K. Damas
T Cells in Coronary Artery Disease: Different Effects of Different T-Cell Subsets
J. Am. Coll. Cardiol., October 9, 2007; 50(15): 1459 - 1461.
[Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
J. Barlic and P. M. Murphy
Chemokine regulation of atherosclerosis
J. Leukoc. Biol., August 1, 2007; 82(2): 226 - 236.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
O. L. Volger, J. O. Fledderus, N. Kisters, R. D. Fontijn, P. D. Moerland, J. Kuiper, T. J. van Berkel, A.-P. J.J. Bijnens, M. J.A.P. Daemen, H. Pannekoek, et al.
Distinctive Expression of Chemokines and Transforming Growth Factor-{beta} Signaling in Human Arterial Endothelium during Atherosclerosis
Am. J. Pathol., July 1, 2007; 171(1): 326 - 337.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
G. S. V. Campanella, J. Grimm, L. A. Manice, R. A. Colvin, B. D. Medoff, G. R. Wojtkiewicz, R. Weissleder, and A. D. Luster
Oligomerization of CXCL10 Is Necessary for Endothelial Cell Presentation and In Vivo Activity
J. Immunol., November 15, 2006; 177(10): 6991 - 6998.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
I. Gotsman, N. Grabie, R. Gupta, R. Dacosta, M. MacConmara, J. Lederer, G. Sukhova, J. L. Witztum, A. H. Sharpe, and A. H. Lichtman
Impaired Regulatory T-Cell Response and Enhanced Atherosclerosis in the Absence of Inducible Costimulatory Molecule
Circulation, November 7, 2006; 114(19): 2047 - 2055.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A.-K. L. Robertson and G. K Hansson
T Cells in Atherogenesis: For Better or For Worse?
Arterioscler. Thromb. Vasc. Biol., November 1, 2006; 26(11): 2421 - 2432.
[Abstract] [Full Text] [PDF]